Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07133594
Active, not recruiting Not applicable

Validation of a Questionnaire in the French Language for the Patient Experience in Radiotherapy

NCT07133594 · tracked via the Priya Life Science France tracker
Sponsor
Centre Leon Berard
Phase
Not applicable
Started
2025-08-07
Last updated
2025-08-21

Condition(s) studied

Validation RTEQ (RadioTherapy Experience Questionnaire) in FrenchPatients Requiring Radiotherapy

Investigational drug(s) / intervention(s)

RTEQ (RadioTherapy Experience Questionnaire) in FrenchEORTC PATSAT-C33 questionnaire

RTEQ (RadioTherapy Experience Questionnaire) in French: Complete the RTEQ questionnaire translated and adapted to the French language in patients receiving external radiotherapy. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.

EORTC PATSAT-C33 questionnaire: Complete the EORTC-PATSAT-C33 questionnaire after completing the RTEQ questionnaire. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.

Study summary

More than 50% of cancer patients have radiotherapy (RT) as part of their care pathway. Scientific and technological advances leads to an increase in demand. The development of hypofractionation is also increasing the capacity to treat more patients. These transformations raise questions from an organizational point of view, the quality of care and the response to patient needs.

Several publications highlight that evaluating patient's experience, satisfaction, and collecting their ideas are excellent foundations for delivering patient-centered care (3,4). To assess the patient experience in RT, Olausson et al. developed and validated a questionnaire in English. To this day , this questionnaire has not been validated in French.

The main objective is to validate the psychometric property of reliability of the Radiotherapy Experience Questionnaire (RTEQ) after its adaptation into French. This project also includes an assessment of patient satisfaction regarding their RT care pathway.

This study is part of a broader initiative aimed at redesigning the patient journey in radiotherapy, and innovating in the tools and in the overall care approach.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>= 18 years * Patient requiring curative external radiotherapy (at least 2 sessions) * Patient covered by a medical insurance * Patient informed and not opposing to the study Exclusion Criteria: * Patient who don't understand or can't read French * Any congitive impairment or condition likely to limit the use of scales and questionnaires * Patient requiring tutorship or curatorship or patient deprived of liberty

Primary outcome measure(s)

  • To validate the psychometric reliability property (internal consistency between items) of the RTEQ questionnaire after translation and adaptation to the French language for the evaluation of the experience of patients receiving external RT. — Time n°1 : Between Day 2 and Day 7 of radiotherapy
    Cronbach's alpha coefficient for each dimension of the RTEQ from the questionnaire items at Time n°1 (T1)

Trial sites (1)

FacilityCityRegionStatus
Centre Leon Berard Lyon France

More Centre Leon Berard trials in France

Clinical and BIOgical Analyses of RECtal Tumors Starting soon
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma Recruiting
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies Active, not recruiting
Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. Active, not recruiting
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07133594 on ClinicalTrials.gov ↗ ← All trials in France